Chemotherapeutic agents and the skin: An update
Authors:
- Haley NaikHNHaley Naik
- Susan BurginSBSusan Burgin
- 1 April 2008
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 58 (4) , 545-570
Abstract
No abstract availableKeywords
This publication has 262 references indexed in Scilit:
- Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myelomaJournal of the American Academy of Dermatology, 2006
- Dermatologic side effects associated with the epidermal growth factor receptor inhibitorsJournal of the American Academy of Dermatology, 2006
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinibJournal of the American Academy of Dermatology, 2006
- Imatinib-induced eccrine squamous syringometaplasiaJournal of the American Academy of Dermatology, 2006
- AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLBritish Journal of Cancer, 2006
- Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patientsEuropean Journal of Cancer, 2005
- Gemcitabine-associated scleroderma-like changes of the lower extremitiesJournal of the American Academy of Dermatology, 2004
- Hypersensitivity to paclitaxel manifested as a bullous fixed drugeruptionJournal of the American Academy of Dermatology, 1996